NKGen Biotech, Inc.
News
NKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Globe Newswire Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive...\n more…
NKGen Biotech Expands Agreement Terms and Restructures COO Role
TipRanks Financial Blog NKGen Biotech ( ($NKGN) ) has provided an update. NKGen Biotech, Inc. has amended its forward purchase agreement to increase both the prepayment shortfall and the s...\n more…
NKGen Biotech to Showcase at Global Investment Conference
TipRanks Financial Blog NKGen Biotech ( ($NKGN) ) has shared an update. NKGen Biotech, Inc. is set to join the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024...\n more…
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire SANTA ANA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ( NKGen or the Company ), a clinical-stage biotechnology company focused on the development and...\n more…
NKGen Biotech receives non-compliance notification from Nasdaq
Seeking Alpha - Healthcare NKGen Biotech receives non-compliance notification from Nasdaq...\n more…
